Vice President and Global Head
Master Magnetics Inc
Wim Tamminga joined QPS in 2010 as Division Director Clinical Pharmacology. In this position he is responsible for the phase I/IIa clinical pharmacology unit overseeing subject recruitment, medical affairs, clinical operations and project management at QPS Netherlands. Currently, he also acts as Global Head of Early Phase Clinical taking responsibility for the harmonization across QPS’ six phase I sites. Prior to joining QPS, Wim worked for over 20 years in the Phase I/IIa business space where he held different management positions in bioanalysis, clinical project management, data management, biostatistics and report writing. He also headed a 80-bed phase I clinical pharmacology unit in the United States which substantially grew under his leadership. Having been involved in over 200 clinical trials, Wim has a wealth of experience in clinical pharmacology including many first in man, DDI, proof of concept and radiolabeled studies. He has a keen interest in pharmacogenetics especially of the CYP450 enzymes. As he worked in both Europe and the US, he has a good understanding of regulations in both Europe and the US. Wim has an undergraduate degree in analytical chemistry and holds a Ph.D. degree in pharmaceutical sciences.
medical affairs, clinical operations and project management